Gyre Therapeutics (GYRE) Retained Earnings (2010 - 2026)
Gyre Therapeutics (GYRE) reported Retained Earnings of -$77.7 million for Q1 2026, down 9.7% year-over-year from -$86.0 million in Q1 2025, and down 13.51% quarter-over-quarter from -$68.4 million in Q4 2025.
Gyre Therapeutics (GYRE) Retained Earnings (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 17 years of Retained Earnings data on file, last reported at -$77.7 million in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$77.7 million, down 9.7% year-over-year; the trailing twelve-month figure through Mar 2026 was -$77.7 million (down 9.7% YoY), and the FY2025 annual result was -$68.4 million, down 2534.81% from the prior year.
- Retained Earnings fell to -$77.7 million in Q1 2026 per GYRE's latest filing, from -$68.4 million in the prior quarter.
- Over five years, Retained Earnings peaked at $7.4 million in Q4 2022 and troughed at -$417.2 million in Q1 2022.
- A 5-year average of -$170.6 million and a median of -$74.5 million in 2024 frame the typical range for Retained Earnings.
- On a YoY basis, Retained Earnings climbed as much as 101.84% in 2022 and fell as far as 37048300.0% in 2022.
- A 5-year view of Retained Earnings shows it stood at $7.4 million in 2022, then plunged by 122.23% to -$1.6 million in 2023, then sank by 57.97% to -$2.6 million in 2024, then slumped by 2534.81% to -$68.4 million in 2025, then declined by 13.51% to -$77.7 million in 2026.
- Business Quant data shows GYRE's Retained Earnings at -$77.7 million in Q1 2026, -$68.4 million in Q4 2025, and -$66.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | -77.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -77.67 Mn |
| Dec 31, 2025 | -68.43 Mn |
| Sep 30, 2025 | -66.70 Mn |
| Jun 30, 2025 | -2.29 Mn |
| Mar 31, 2025 | -70.80 Mn |
| Dec 31, 2024 | -2.60 Mn |
| Sep 30, 2024 | -73.40 Mn |
| Jun 30, 2024 | -74.50 Mn |
| Mar 31, 2024 | -78.00 Mn |
| Dec 31, 2023 | -1.64 Mn |
| Sep 30, 2023 | -414.70 Mn |
| Jun 30, 2023 | -413.15 Mn |
| Mar 31, 2023 | -410.68 Mn |
| Dec 31, 2022 | 7.40 Mn |
| Sep 30, 2022 | -370.48 Mn |
| Jun 30, 2022 | -365.60 Mn |
| Mar 31, 2022 | -417.20 Mn |
| Dec 31, 2021 | -402.69 Mn |
| Sep 30, 2021 | 1,000.00 |
| Jun 30, 2021 | -357.10 Mn |